BPS Bioscience Offers Immunotherapy Cell Lines for Rent

SAN DIEGO - Aug. 26, 2016 - PRLog -- Immunotherapy has emerged as a promising therapeutic approach for a variety of human cancers, particularly melanoma, lung, and kidney cancers. The FDA approval of nivolumab and ipilimumab in 2015 has ushered in a new era of therapeutic strategies to stimulate the immune system by targeting immune checkpoint proteins. Currently there are dozens of promising immunotherapies in clinical trials, many of which appear to be close to receiving FDA approval.

The drive by both the pharmaceutical industry and academic researchers to efficiently commercialize innovative immunotherapies has underscored the need for recombinant cell lines and other tools for cell-based drug discovery.  Cell-based assays offer a biologically relevant way to study these immune pathways in a cellular context.

In order to facilitate the drug discovery process, BPS Bioscience is instigating a new program to allow researchers to lease some of its most popular immunotherapy cell lines for up to three months. This program will allow scientists a low-cost, low risk option for validating the suitability of these unique cell lines in their own laboratories

"BPS understands the need for the development and dissemination of cell lines and other tools for drug discovery," said Henry Zhu, President and CEO of BPS Biosciences, Inc.  "We believe it is important to make these unique cell lines available to researchers with limited budgets, and to encourage investigations using these cells in new applications."

Currently, BPS offers many of its immunotherapy-related cell lines on a trial basis, including cells expressing key immune checkpoint proteins such as PD-1, PD-L1, IDO1, and TDO. BPS plans to expand the number of immunotherapy cell lines available for rental in the coming months.

To learn more about BPS Bioscience's recombinant cell lines, immunotherapy products and services, visit http://www.bpsbioscience.com

About BPS Bioscience, Inc.

Headquartered in San Diego, California, BPS Bioscience, Inc. is a leading manufacturer of products for Immunotherapy research, as well as Epigenetics (Acetyltransferases, HDACs, Histone Demethylases, Methyltransferases, PARPs, and Bromodomains), Cytokines, Immune Checkpoint Proteins, Kinases, Phosphatases, Phosphodiesterases, Proteases, Ubiquitin Enzymes, and other Metabolic Enzymes. BPS offers one of the largest selections of recombinant enzymes and assay kits for drug discovery and continues to expand its portfolio of innovative drug discovery products. BPS also provides custom protein expression, biochemical and cell-based assays, and compound screening and profiling services. BPS has provided products and services to pharmaceutical companies and academic institutes in over 45 countries worldwide. BPS's focus on providing quality life science products and services in a timely manner helps our customers to accelerate drug discovery and development for the treatment of human diseases. Visit BPS's website for more information at http://www.bpsbioscience.com